Search Results: spinraza

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

Posted in , ,

Biogen Inc. announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA […]

Read More ›

Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA

Posted in ,

• Alcyone’s ThecaFlex DRx™ System is an implantable medical device in development to enable routine subcutaneous administration of therapeutics to the cerebrospinal fluid• First stage […]

Read More ›

Spinraza®

Spinraza® Spinraza® was the first FDA-approved therapy to treat spinal muscular atrophy (SMA). It is an SMN-enhancing therapy that works by targeting the SMN2 gene, […]

Read More ›

Biogen Presents New Spinraza Data at the 2021 Virtual SMA Conference

Posted in , ,

Biogen Inc., today announced new research supporting the continued development of an investigational higher dose of SPINRAZA® (nusinersen) and additional data reinforcing the strength of […]

Read More ›

Biogen Shares New Spinraza Data Exploring Opportunities to Improve Outcomes for SMA Patients

Posted in , , ,

Biogen has shared new data from the Spinraza (nusinersen) clinical development program aimed at optimizing outcomes for people with SMA and advancing understanding of the […]

Read More ›

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of Spinraza in Patients Treated with Zolgensma

Posted in ,

Biogen Inc., today announced, it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA (nusinersen) […]

Read More ›

Biogen Shares Results from Landmark NURTURE Study of Pre-Symptomatic SMA Patients Treated with Spinraza

Posted in ,

      Biogen, Inc., today announced new results from NURTURE, the longest study of pre-symptomatic patients with spinal muscular atrophy (SMA), which is transforming […]

Read More ›

Biogen Shares SPINRAZA Research Update

Posted in ,

New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of SMA Patients Biogen Inc. recently announced additional data from the SPINRAZA […]

Read More ›

Biogen Announces First Patient Treated With Higher Dose Of Spinraza In Phase 2/3 DEVOTE Study

Posted in ,

Biogen today announced that the first patient has been treated in the global clinical study, DEVOTE. The study is designed to evaluate the safety, tolerability, […]

Read More ›

Biogen Issues Q4 2019 Community Statement on Spinraza

Posted in ,

Dear Members of the SMA Community, As part of Biogen’s ongoing commitment to individuals living with, and caregivers affected by, spinal muscular atrophy (SMA), we […]

Read More ›
Scroll to Top